MedTrace Logo

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

NCT05291039 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-03-28

No results posted yet for this study

Summary

This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.

Conditions

  • Inflammatory Bowel Diseases

Interventions

DRUG

Infliximab

group 1 (n=20): patients will receive IFX

DRUG

Adalimumab

group 2 (n=20): patients will receive ADA

Sponsors & Collaborators

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass Prof. · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-03-30
Completion
2023-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05291039 on ClinicalTrials.gov